Gilead Signs a License Agreement with Zydus and Dr. Reddy’s for Remdesivir to Treat COVID-19

 Gilead Signs a License Agreement with Zydus and Dr. Reddy’s for Remdesivir to Treat COVID-19

Gilead Signs a License Agreement with Zydus and Dr. Reddy’s for Remdesivir to Treat COVID-19

Shots

  • Gilead signs a non-exclusive licensing agreement with Zydus to manufacture and distribute remdesivir, under which Zydus to receive the manufacturing know-how from Gilead to manufacture the API for remdesivir and the finished product and market it in 127 countries, including India
  • The license is royalty-free until another pharmaceutical product or vaccine receives the US FDA and EMA’s approval for COVID 19 or the WHO announcing the end of the public health emergency. Zydus will ramp up the production to reach patients across the 127 countries including India in Gilead’s global patient solution region
  • Additionally, Gilead signed a non- exclusive agreement with Dr. Reddy’s to register, manufacture and commercialize Gilead’s remdesivir for Covid-19 in 127 countries including India. Dr. Reddy’s will receive Gilead’s technology transfer for manufacturing scale-up and obtain regulatory approval for marketing of therapy in respective countries

Click here, Click here to read full press release/ article | Ref: Zydus, Businesswire | Image: Gilead

Related News: Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post